PT - JOURNAL ARTICLE AU - Hart, WS AU - Miller, E AU - Andrews, NJ AU - Waight, P AU - Maini, PK AU - Funk, S AU - Thompson, RN TI - Generation time of the Alpha and Delta SARS-CoV-2 variants AID - 10.1101/2021.10.21.21265216 DP - 2021 Jan 01 TA - medRxiv PG - 2021.10.21.21265216 4099 - http://medrxiv.org/content/early/2021/10/23/2021.10.21.21265216.short 4100 - http://medrxiv.org/content/early/2021/10/23/2021.10.21.21265216.full AB - Background In May 2021, the Delta SARS-CoV-2 variant became dominant in the UK. This variant is associated with increased transmissibility compared to the Alpha variant that was previously dominant. To understand ongoing transmission and interventions, a key question is whether the Delta variant generation time (the time between infections in infector- infectee pairs) is typically shorter–i.e., transmissions are happening more quickly–or whether infected individuals simply generate more infections.Methods We analysed transmission data from a UK Health Security Agency household study. By fitting a mathematical transmission model to the data, we estimated the generation times for the Alpha and Delta variants.Results The mean intrinsic generation time (the generation time if there had been a constant supply of susceptibles throughout infection) was shorter for the Delta variant (4·6 days, 95% CrI 4·0-5·4 days) than the Alpha variant (5·5 days, 95% CrI 4·6-6·4 days), although within uncertainty ranges. However, there was a larger difference in the realised mean household generation time between the Delta (3·2 days, 95% CrI 2·4-4·2 days) and Alpha (4·5 days, 95% CrI 3·7-5·4 days) variants. This is because higher transmissibility led to faster susceptible depletion in households, in addition to the reduced intrinsic generation time.Conclusions The Delta variant transmits more quickly than previously circulating variants. This has implications for interventions such as contact tracing, testing and isolation, which are less effective if the virus is transmitted quickly. Epidemiological models of interventions should be updated to include the shorter generation time of the Delta variant.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWSH was funded by an EPSRC Excellence Award for his doctoral studies (Grant Reference EP/R513295/1). EM receives support from the National Institute for Health Research (NIHR) Health Protection Research Unit in Immunisation at the London School of Hygiene and Tropical Medicine in partnership with the UKHSA (Grant Reference NIHR200929). SF receives funding from the Wellcome Trust (Grant Reference 210758/Z/18/Z). RNT receives support from the UKRI (Grant Reference EP/V053507/1).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The household surveillance protocol was approved by the UKHSA Research Ethics and Governance Group as part of the portfolio of the UKHSA's enhanced surveillance activities in response to the pandemic. Oral informed consent for sampling and follow up was obtained by the nurses from household members who were free to decline to participate in the surveillance at any time. Consent for children was obtained by a parent or legal guardian. Only anonymised data were provided to non-UKHSA authors.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at https://github.com/will-s-hart/variant_generation_times.